miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In aggressive prostate cancers, the oncoprotein STMN1 (also known as stathmin 1 and oncoprotein 18) is often overexpressed. STMN1 is involved in various cellular processes, including cell proliferation, motility, and tumor metastasis. Here, it was found that the expression of STMN1 RNA and protein is elevated in metastatic prostate cancers. Knockdown of STMN1 resulted in reduced proliferation and invasion of cells and tumor growth and metastasis in vivo. Furthermore, miR-34a downregulated STMN1 by directly binding to its 3′-UTR. Overexpression of miR-34a in prostate cancer cells reduced proliferation and colony formation, suggesting that it is a tumor suppressor. The transcriptional corepressor C-terminal binding protein 1 (CtBP1) negatively regulated expression of miR-34a. Furthermore, gene expression profiling of STMN1-modulated prostate cancer cells revealed molecular alterations, including elevated expression of growth differentiation factor 15 (GDF15), which is involved in cancer progression and potentially in STMN1-mediated oncogenesis. Thus, in prostate cancer, CtBP1-regulated miR-34a modulates STMN1 expression and is involved in cancer progression through the CtBP1\miR-34a\STMN1\GDF15 axis. Implications: The CtBP1\miR-34a\STMN1\GDF15 axis is a potential therapeutic target for treatment of aggressive prostate cancer. Mol Cancer Res; 16(7); 1125–37. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
Chandrashekar, D. S., Bashel, B., Balasubramanya, S. A. H., Creighton, C. J., Ponce-Rodriguez, I., Chakravarthi, B. V. S. K., & Varambally, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.05.002 · Cited by 6,086
Self-citationDocetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
MicroRNAs in cancer: biomarkers, functions and therapy
Hayes, J., Peruzzi, P. P., & Lawler, S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.005 · Cited by 2,049 · cited 1×
“miRNAs participate in tumorigenesis through modulating the expression of their cognate target genes by binding to the 30-untranslated regions (UTR) of target mRNAs, causing their translational inhibition or cleavage (31).”
Background
Cited by
The comprehensive landscape of miR-34a in cancer research
Li, S., Wei, X., He, J., Cao, Q., Du, D., Zhan, X., Zeng, Y., Yuan, S., & Sun, L. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09973-3 · Cited by 84
miRNAs as therapeutic tools and biomarkers for prostate cancer
Arrighetti, N., & Beretta, G. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030380 · Cited by 43
Fan, K., Ni, X., Shen, S., Gong, Z., Wang, J., Xin, Y., Zheng, B., Sun, W., Liu, H., Suo, T., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01051-z · Cited by 6
Metadata
- Authors
- Chakravarthi, B. V. S. K., Chandrashekar, D. S., Agarwal, S., Balasubramanya, S. A. H., Pathi, S. S., Goswami, M. T., Jing, X., Wang, R., Mehra, R., Asangani, I. A., Chinnaiyan, A. M., Manne, U., Sonpavde, G., Netto, G. J., Gordetsky, J., & Varambally, S.
- Venue
- Molecular Cancer Research
- Published
- 2018-07-01
- Volume
- 16
- Issue
- 7
- Pages
- 1125-1137
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2762769581
- Cited by
- 59
- References
- 7
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-17-0230
- The paper
- Chakravarthi, B. V. S. K., Chandrashekar, D. S., Agarwal, S., Balasubramanya, S. A. H., Pathi, S. S., Goswami, M. T., Jing, X., Wang, R., Mehra, R., Asangani, I. A., Chinnaiyan, A. M., Manne, U., Sonpavde, G., Netto, G. J., Gordetsky, J., & Varambally, S. (2018). miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-17-0230
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.